An Implantable Sensor ‘LAP-Sense’ for Remote/Continuous Monitoring of Complex Cardiovascular Patients

每年，心血管疾病（CVD）导致的死亡占全球死亡总数的24%，即每年1800万人，其中85%的死亡是由于中风、心力衰竭（HF）和心房颤动（AF）。英国有超过600万心血管疾病患者，每年花费74亿英镑的医疗费用和158亿英镑的经济损失。传统上，临床医生关注生理指标（患者体重/血压等）来检测心血管疾病的恶化。不幸的是，这些标记在失代偿的时间过程中出现较晚。在需要住院治疗之前，依靠它们几乎没有时间做出反应。许多研究表明房颤驱动心衰病理生理，反之亦然。根据弗雷明汉心脏研究，57%的心衰患者发生房颤。这大大增加了住院、中风和死亡的风险。因此，这就提出了一个强有力的案例，即采用一种设备同时治疗心衰和AF的最大风险，即中风。目前治疗这些患有房颤和心衰的复杂患者的方法需要多种昂贵的设备和危险的手术。通过这个项目，RECO和他们的合作伙伴AuriGen正在开发世界上第一个植入式心脏监测传感器“LAP-Sense”，用于远程/连续监测CVD患者，该传感器与左心房附件闭塞（LAAO）设备完全集成。这项为期18个月的工业研究项目利用了RECO的传感器技术，该技术将与AuriGen的Zenith设备集成，用于LAP监测和LAAO。RECO & AuriGen基于心脏病专家的反馈和要求，正在开发一种产品，以协同解决数百万房颤和心衰患者的需求。除了LAAO的卒中预防能力之外，这将提供改进的诊断，在同一程序中植入单个设备，将当前的护理标准提升到安全性、有效性和成本效益的新水平。

Every year, Cardiovascular Disease (CVD) causes 24% of all deaths worldwide or 18million/annum, with 85% of fatalities due to stroke, heart failure (HF) and atrial fibrillation (AF). The UK has over 6 million CVD sufferers, costing £7.4billion/annum in healthcare costs and £15.8billion/annum in economic losses.Traditionally, clinicians have focused on physiological markers (patient-weight/blood-pressure etc) to detect worsening CVD. Unfortunately, these markers appear late in the time course of decompensation. Relying on them leaves little time to respond before hospitalization is necessary.Many studies have shown that AF drives HF pathophysiology and vice versa. According to the Framingham Heart Study, AF occurred in 57% of the individuals with HF. This leads to huge increased risk of hospitalization, stroke and death. Therefore, this presents a strong case to have a single device that simultaneously treats both HF and the greatest risk of AF, namely stroke. Current approaches to treat these complex patients, suffering from AF & HF, requires multiple expensive devices and risky procedures.Through this project, RECO and their collaborator AuriGen are developing world's first implantable cardiac monitoring sensor 'LAP-Sense' for remote/continuous monitoring of CVD patients, which is fully integrated with a Left Atrial Appendage Occlusion (LAAO) device. This 18-month industrial research project utilizes RECO's sensor technology, which will be integrated with AuriGen's Zenith device to be used for LAP monitoring and LAAO.RECO & AuriGen, based on feedback and requests from cardiologists, are developing a product to synergistically address needs of millions AF & HF sufferers. This will offer improved diagnostics in addition to the stroke prevention capabilities of an LAAO, in a single device, implanted in the same procedure, elevating the current standard of care to new levels of safety, efficacy and cost effectiveness.